ARZERRA (ofatumumab) injection

ARZERRA is a brand-name prescription drug that’s FDA-approved to treat chronic lymphocytic leukemia (CLL). Brand Name: ARZERRA (ofatumumab) injection, for intravenous use Initial U.S. Approval: 2009.

Home | (ofatumumab) injection

ARZERRA (ofatumumab) injection Price In India and Overseas
ARZERRA (ofatumumab) injection

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Overseas Patient/ Export inquires.

Call / WhatsApp Number
+91 9643240915 (Mr. Yashpal Singh)
+91 9289711087 (Ms. Sana Sadyar)

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

ARZERRA (ofatumumab) injection

Ofatumumab (Arzerra 100 mg or 1000 mg concentrate for solution for infusion) is indicated for the treatment of untreated, relapsed, or refractory chronic lymphocytic leukemia (CLL).

Arzerra is a brand-name prescription drug that’s FDA-approved to treat chronic lymphocytic leukemia (CLL). CLL is a type of cancer that affects your white blood cells. Ofatumumab (Arzerra 100 mg or 1000 mg concentrate for solution for infusion) is indicated for the treatment of untreated, relapsed, or refractory chronic lymphocytic leukemia (CLL). Ofatumumab (Arzerra) was then approved in the European Union in June 2010, in the United Kingdom in April 2010, and in Canada in August 2012.

Ofatumumab, A drug used alone or with other drugs to treat certain types of chronic lymphocytic leukemia. It is also being studied in the treatment of other types of cancer. Ofatumumab binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of leukemia and lymphoma cells. Ofatumumab may block CD20 and help the immune system kill cancer cells. It is a type of monoclonal antibody. Also called Arzerra and HuMax-CD20. Ofatumumab is approved to be used alone or with other drugs to treat: Chronic lymphocytic leukemia (CLL). Ofatumumab is also being studied in the treatment of other types of cancer.
https://www.cancer.gov/publications/dictionaries/cancer-terms/def/ofatumumab

Drug (Brand / Generic): ARZERRA / Ofatumumab
Current Indications: chronic lymphocytic leukemia (CLL)
Marketed by:: Novartis Pharmaceuticals Corporation
Approval Date: October 27, 2009

Available as (Form & Strength): • 100 mg/5 mL single-use vial for intravenous infusion. & • 1,000 mg/50 mL single-use vial for intravenous infusion.
ARZERRA is supplied at a concentration of 20 mg/mL in single-use vials. Each single-use vial contains either 100 mg ofatumumab in 5 mL of solution or 1,000 mg ofatumumab in 50 mL of solution.

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India is certified pharmaceutical facilitator / supplier / importer based in india. They are also who GDP certified. One of the pharmaceutical products they offer is “ARZERRA (ofatumumab) injection”.

Confirmation of the order for ARZERRA (ofatumumab) injection will be subject to the submission of a valid doctor’s prescription and, if applicable, an import permit.

We have delivered medicines to following cities in India –  Ahmedabad, Aizawal, Aurangabad, Barshi, Bengaluru, Bhopal, Cachar, Chennai, Dibrugarh, Hyderabad, Karungapally, Kohima, Kollam, Kolkata, Mumbai, Meghalaya, Mizoram, Sikkim, Nagpur, New Delhi, Pondichery, Pune, Punjab, Thirunananthapuram, Tripura, Wardha

ALS serves as a facilitator, supplier & exporter in India assisting patients, doctors, and hospitals in importing the prescription medicine brand ARZERRA (ofatumumab) injection. The import process requires a valid prescription and an Import License in the Patient’s Name.

For patients from following foreign countries seeking access to ARZERRA (ofatumumab) injection, they can inquire and find further information by sending their inquiries to ALS.

We have delivered medicines to following countries – Argentina, Australia, Austria, Azerbaijan, Bahrain, Brazil, Bulgaria, Cambodia, Canada, Chile, Colombia, Costa Rica, Croatia, Cyprus, Denmark, Dominican Republic, Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Guatemala, India, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kenya, Kuwait, Latvia, Lebanon, Libya, Lithuania, Malawi, Mexico, Montenegro, Nepal, Netherlands, New Zealand, Nigeria, Norway, Oman, Pakistan, Paraguay, Peru, Poland, Qatar, Romania, Saudi Arabia, Serbia, Singapore, Slovenia, Spain, Sri Lanka, Sweden, Switzerland, United Arab Emirates, United Kingdom, United States, Venezuela, Zimbabwe.

Kindly reach out to us for ARZERRA (ofatumumab) injection price and availability confirmation.
The price of the medicines is the cost set by the manufacturer. In addition, Named Patient support fee, shipping costs and any local tax (if applicable) will apply.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.